Oral antiplatelets and outcomes
PEGASUS-TIMI 54: la duplice antiaggregazione con aspirina e ticagrelor a lungo termine riduce gli eventi trombotici ma aumenta le emorragie in pazienti con pregresso infarto miocardico - CardioInfo
PEGASUS-TIMI 45 Trial – Carlsibicky Internal Medicine APPE Blog
Three-year safety and efficacy outcomes of the PEGASUS-TIMI-54 trial. a... | Download Scientific Diagram
TCT 78: Efficacy of Long-term Ticagrelor in Stented Patients in PEGASUS-TIMI 54 | tctmd.com
Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial - ScienceDirect
Long‐Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS‐TIMI 54 Trial | Journal of the American Heart Association
Multivessel Disease Patients See Benefits of Long-term Ticagrelor: PEGASUS-TIMI 54 Analysis | tctmd.com
Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy | JACC: Cardiovascular Interventions
PDF) Efficacy and Safety with Ticagrelor in Patients with Prior Myocardial Infarction in the Approved European label: Insights from PEGASUS-TIMI 54
Davide Capodanno on Twitter: "DAPT or DPI in high risk CCS? A few differentiating aspects to aid decisions in patients at low bleeding risk: 1) prior stroke excluded in PEGASUS 2) longer
![PDF] Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/0481a5638e69a8039cd62b6f882832b7e1b98346/3-Table1-1.png "PDF] Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial. | Semantic Scholar")
PDF] Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial. | Semantic Scholar
PLATO & PEGASUS Bleeding | BRILINTA® (ticagrelor) tablets | For HCPs
Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin–Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial -
Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54 | Journal of the American Heart Association
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI. - ppt download
![PDF] Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54 | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/cfb28c5737c40589e026a13b4dcce810fc8777f3/5-Figure2-1.png "PDF] Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54 | Semantic Scholar")
PDF] Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54 | Semantic Scholar
Beneficio clinico del ticagrelor a lungo termine nei pazienti con vasculopatia periferica - ATBV
PLATO & PEGASUS Efficacy | BRILINTA | For HCPs
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction | NEJM
Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54 - ScienceDirect
PEGASUS-TIMI 54 – TIMI STUDY GROUP
Ticagrelor per la prevenzione secondaria degli eventi cardiovascolari nei pazienti con coronaropatia multivasale - ATBV
Strategie antitrombotiche a lungo termine nel paziente post-infarto | Giornale Italiano di Cardiologia - Organo ufficiale di Italian Federation of Cardiology e Società Italiana di Chirurgia Cardiaca
Davide Capodanno on Twitter: "Notably, the FDA has now approved 4 indications for ticagrelor based on regulatory trials: 1) secondary prevention in ACS (PLATO) 2) secondary prevention in prior MI (PEGASUS) 3)
